Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Editas Medicine (EDIT) Interest & Investment Income: 2015-2025

Historic Interest & Investment Income for Editas Medicine (EDIT) over the last 11 years, with Sep 2025 value amounting to $1.8 million.

  • Editas Medicine's Interest & Investment Income fell 48.13% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.8 million, marking a year-over-year decrease of 56.38%. This contributed to the annual value of $14.1 million for FY2024, which is 19.95% down from last year.
  • Editas Medicine's Interest & Investment Income amounted to $1.8 million in Q3 2025, which was down 12.27% from $2.1 million recorded in Q2 2025.
  • Over the past 5 years, Editas Medicine's Interest & Investment Income peaked at $5.1 million during Q3 2023, and registered a low of $134,000 during Q1 2021.
  • Moreover, its 3-year median value for Interest & Investment Income was $3.5 million (2024), whereas its average is $3.5 million.
  • Per our database at Business Quant, Editas Medicine's Interest & Investment Income tumbled by 91.40% in 2021 and then soared by 1,449.71% in 2022.
  • Over the past 5 years, Editas Medicine's Interest & Investment Income (Quarterly) stood at $175,000 in 2021, then soared by 1,449.71% to $2.7 million in 2022, then soared by 88.13% to $5.1 million in 2023, then plummeted by 76.46% to $1.2 million in 2024, then plummeted by 48.13% to $1.8 million in 2025.
  • Its Interest & Investment Income stands at $1.8 million for Q3 2025, versus $2.1 million for Q2 2025 and $2.7 million for Q1 2025.